前言 然而，随着脑机接口技术的不断成熟，我们正在经历一场关于"生命终点"的叙事重构。当数字信号开始接管受损的生物信号，科技不仅在为老年人延长生 命的长度，更是在修补他们的尊严。 宣布量产，脑机接口迎来"奇点时刻" 2026年开年第一天，"钢铁侠"马斯克便抛出了一个重磅消息。 1月1日，马斯克宣布其旗下的神经科技和脑机接口公司Neuralink将在2026年进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流程"。这 一消息迅速引发全球关注，因为它标志着脑机接口进入"商业化跃迁"的关键节点。 脑机接口（Brain-Computer Interface）是一种直接在大脑与外部设备之间建立通信路径的技术，广泛用于运动/言语重建、感觉恢复、神经调控与人机交互 等场景。科幻电影《黑客帝国》中，男主角尼奥的"脑后插管"，或许就是脑机接口最初的想象。 图源：X 图源：电影《黑客帝国》剧照 如果站在更久远的未来回望，2026年或许是科幻加速踏进现实的开始。 衰老——曾被视为不可逆的命运，伴随着肌肉的萎缩，人类的意识仿佛只能在渐深的黑暗中走向消亡。 然而，现实中的脑机接口技术发展，早已超越了科幻作品。如今，这项技术 ...

Core Viewpoint - BrainCo has secretly submitted a listing application to the Hong Kong Stock Exchange, aiming to become the first company in the global brain-computer interface (BCI) sector to enter the public capital market [1][10]. Technology Choice - Founded by Harvard dropout Han Bicheng in 2015, BrainCo chose a non-invasive BCI technology route, contrasting with Neuralink's invasive approach [2][12]. - BrainCo's technology collects brain signals through super sensors without surgical implantation, focusing on practical applications and scalability [2][12]. - The company has achieved significant milestones, including enabling amputees to control prosthetic limbs with their thoughts, addressing a market of 24 million disabled individuals in China [12][14]. Commercial Breakthrough - BrainCo's business strategy is pragmatic, starting with clear medical needs and expanding into consumer applications [4][14]. - The company has seen a substantial increase in sales, with 2024 quarterly sales projected to be four to five times that of 2023 [4][14]. - BrainCo's products include smart prosthetic hands and attention training systems, creating a dual-driven model of "medical rehabilitation + consumer applications" [4][14]. Capital Competition - The BCI industry is on the verge of explosive growth, with Morgan Stanley predicting a $400 billion market in the U.S. by 2045 [15]. - BrainCo has raised approximately 2 billion RMB, marking the second-largest financing record in the global BCI sector after Neuralink [15]. - The company’s decision to list in Hong Kong aligns with the trend of Chinese companies returning to the market and aims to enhance its global influence [15]. Industry Resonance - The news of BrainCo's listing application has triggered a positive response in the capital market, with related stocks rising significantly [16]. - BrainCo's listing is seen as a critical indicator of the BCI industry's development, contrasting with Neuralink's focus on disruptive innovation [16]. - The market reflects differing valuation perspectives, with investors weighing the commercial viability of BrainCo against the speculative nature of Neuralink's technology [16].

Core Viewpoint - The market shows strength with major indices rising, particularly in AI applications and precious metals, while adjustments in certain sectors are seen as profit-taking rather than panic [1]. Group 1: AI Applications - AI application sector continues to strengthen, with stocks like Zhejiang Wenhui and Shiji Information hitting daily limits, and others like Guangyun Technology and Zhidema rising over 10% [2][3]. - Google announced partnerships with major retailers to develop AI applications for e-commerce, indicating a broadening commercial space for AI [3]. Group 2: Market Analysis - Everbright Securities suggests that recent market adjustments are primarily due to profit-taking, with a structural shift from high-performing sectors like commercial aerospace to relatively lower-performing sectors [4]. - The market is not in a state of panic, and a structural market trend is expected to continue, with indices likely to experience fluctuations [4]. Group 3: AI in Healthcare - CITIC Securities reports that AI in healthcare is set to accelerate the restructuring of the trillion-dollar pharmaceutical market, with clearer payment structures expected by 2026 [5]. - Key areas of focus include AI drug development, grassroots AI healthcare applications, and AI pathology diagnostics [5]. Group 4: Brain-Computer Interface Technology - Galaxy Securities highlights the transition of brain-computer interface technology from laboratory settings to industrial production, with significant developments expected from companies like Neuralink [6]. - The industry is supported by government policies and healthcare pricing strategies, facilitating commercialization and innovation [6]. Group 5: Space Photovoltaics - Guojin Securities identifies space photovoltaics as a key segment within the commercial aerospace sector, expected to be a leading theme in the new energy sector by 2026 [7]. - The market is recognizing the value and potential of space photovoltaics, with ongoing developments in related equipment and materials [7].

1月8日，据工业和信息化部官网，工业和信息化部、中央网信办、国家发展改革委、教育部、商务部、 国务院国资委、市场监管总局、国家数据局等八部门联合印发《"人工智能+制造"专项行动实施意 见》，加快脑机接口的产业化、商业化进程。 万联证券发布研报称，政策意见指出加快脑机接口的产业化、商业化进程。目前脑机接口行业全球竞争 格局呈"美国主导侵入式、中国领跑非侵入式"的发展格局，竞争要素聚焦"电极、芯片、算法"三大核 心。短期内脑机接口商业化更多聚焦在非侵入式，中长期核心在(半)侵入/侵入式"柔性电极+高通量低功 耗芯片"等上游技术、多中心临床、合规标准等综合系统能力。行业政策支持和医保支付、注册临床节 点突破、核心技术突破和国产替代等均为未来行业发展催化剂。 脑机接口相关概念港股： 心玮医疗-B(06609)、南京熊猫（600775）电子股份(00553)、蓝思科技（300433）(06613)、脑动极光- B(06681)、微创脑科学(02172)、 《意见》提出加速智能终端升级。支持端侧模型、开发应用工具链等技术突破，培育智能手机、电脑、 平板、智能家居等人工智能终端。 聚焦工业巡检、远程医疗等重点场景，加快增强 ...

Group 1 - The core viewpoint of the news is the acceleration of the industrialization and commercialization of brain-computer interface (BCI) technology in China, supported by a joint policy from multiple government departments [1][2] - The policy emphasizes upgrading smart terminals and supporting breakthroughs in edge models and application toolchains, focusing on AI-enabled devices such as smartphones, computers, tablets, and smart home products [1] - The global BCI industry is experiencing rapid development, with a competitive landscape where the U.S. leads in invasive technologies while China excels in non-invasive approaches [2] Group 2 - Recent announcements from companies like Neuralink indicate plans for large-scale production of BCI devices by 2026, highlighting advancements in fully automated surgical processes [1] - The BCI industry encompasses a wide range of sectors, including materials, chips, surgery, and medical rehabilitation, with significant policy support and healthcare pricing measures in place to facilitate commercialization in China [1][2] - Key competitive factors in the BCI industry include electrodes, chips, and algorithms, with a focus on non-invasive commercialization in the short term and a shift towards flexible electrodes and high-throughput low-power chips in the long term [2]

Core Insights - Brain-computer interface (BCI) technology is transitioning from laboratory research to industrial production, with significant advancements expected in the coming years [1] - Neuralink, a company owned by Elon Musk, plans to initiate large-scale production of BCI devices by 2026 and is advancing fully automated surgical procedures [1] - The global BCI industry is experiencing rapid growth, with two main technological paths: invasive and non-invasive methods [1] Industry Overview - The BCI industry encompasses a wide range of sectors, including materials, chips, surgery, and medical rehabilitation [1] - The United States and China are the leading countries in the BCI field, engaging in intense competition [1] - The U.S. has accumulated significant advancements in invasive frontier technologies, while Chinese companies are quickly catching up due to policy guidance and capital support [1] Policy and Support - In recent years, a series of policies have been introduced at both national and local levels in China, clarifying the development direction of the BCI industry [1] - Support measures such as medical insurance pricing and expedited approval processes have been implemented to facilitate the commercialization and innovation of the BCI industry in China [1]

中国银河证券指出，脑机接口技术正从实验室迈向产业化生产。近期，马斯克旗下公司Neuralink宣布， 计划在2026年启动脑机接口设备的大规模量产，并推进全自动化外科手术流程。全球脑机接口产业正迎 来快速发展，其技术路径主要分为侵入式和非侵入式两种，产业链覆盖材料、芯片、手术及医疗康复等 多个领域。近年来，我国从国家到地方层面密集出台的系列政策以及医保定价、优先审批等支持措施， 明确了脑机接口产业发展方向，并为中国脑机接口产业的商业化落地和创新追赶提供了强力保障。 ...

Group 1 - Zhejiang Qiangnao Technology Co., Ltd. has secretly submitted an IPO application in Hong Kong, aiming to raise several hundred million dollars [1][2] - The company recently completed a financing round of approximately 2 billion RMB, making it the second-largest single financing in the global brain-computer interface sector, following Neuralink [1][2] - The financing attracted participation from notable investors including IDG, Huaden International, and leading manufacturing companies, indicating strong market expectations for the commercialization of non-invasive brain-computer interfaces [1][2] Group 2 - Qiangnao Technology aims to help 1 million physically disabled individuals regain daily life through neural-controlled prosthetics within the next five to ten years [2] - The company plans to use the funds raised from the IPO to accelerate core technology research and development, engineering breakthroughs, and product scaling [1][2] - The involvement of major manufacturing and technology firms in the financing round suggests a collaborative effort to enhance hardware production capabilities and core component synergies [2][3] Group 3 - The brain-computer interface sector is experiencing significant growth, with a projected global market size of $12.4 billion by 2034 and a Chinese market size of 6.14 billion RMB by 2028 [6] - Recent positive developments in the sector, including the establishment of industry standards and participation in major medical investment conferences, have energized the market [4] - Brain-computer interface concept stocks have shown strong performance, with several companies experiencing significant stock price increases [4][5]

Core Insights - Strong Brain Technology has reportedly submitted a confidential IPO application to the Hong Kong Stock Exchange, positioning itself as the first technology-based public company in China's brain-computer interface (BCI) sector [1][3] - The company recently completed approximately 2 billion yuan in Pre-IPO financing, achieving a post-investment valuation exceeding 1.3 billion USD [1][3] - The global brain-computer interface market is projected to grow from 1.2 billion USD in 2019 to nearly 2 billion USD in 2023, with a compound annual growth rate (CAGR) exceeding 13% [6] Company Developments - Strong Brain Technology aims to assist 1 million physically disabled individuals by providing neural-controlled prosthetics and improve the lives of 10 million patients suffering from brain-related disorders over the next five to ten years [3] - The company is focused on non-invasive solutions, developing super sensors to detect human neural signals, differentiating itself from competitors like Neuralink [3] - In 2025, the company plans to accelerate its technology innovation and industrialization processes, launching a new generation of bionic dexterous hands for smart manufacturing applications [4] Market Trends - The brain-computer interface sector has been included in China's "14th Five-Year Plan" as one of the six future industries, indicating its transition from laboratory research to a national strategic focus [6] - Following the announcement of BCI-related developments, several companies in the sector, such as Innovation Medical and Rock Mountain Technology, experienced significant stock price movements, highlighting market sensitivity to BCI concepts [6][7] - The capital market's reaction has been mixed, with some companies facing scrutiny from regulatory bodies regarding their BCI-related announcements [6][7]

Investment Rating - The report rates the AI healthcare industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [2][19]. Core Insights - The launch of OpenAI's ChatGPT Health on January 8, 2026, marks a significant advancement in AI healthcare, integrating user health data for personalized health analysis and recommendations. The user base of Ant Group's AI tool, Antifufu, has also seen substantial growth, surpassing 30 million monthly active users [2][5]. - The report highlights the rapid penetration of AI health management in the consumer market, driven by advancements in technology and user engagement [2][5]. - Key areas of progress include AI consultations, brain-computer interfaces, and AI-driven drug development, with notable advancements from companies like Neuralink and Retro Biosciences [10][13][14]. Summary by Sections AI Health Management - OpenAI's ChatGPT Health integrates personal health data, offering features such as test report interpretation, health management, and personalized diet and fitness recommendations. The tool emphasizes user privacy and data security [4][7]. - Antifufu has integrated over 100 AI functions, connecting users with 300,000 real doctors and over 500 AI avatars, achieving a doubling in user engagement metrics within a month [8][9]. AI Consultation and Drug Development - The report notes significant improvements in AI consultation tools, with various companies like Weining Health and JD Health being highlighted for their contributions to AI health management [15]. - In drug development, OpenAI's collaboration with Retro Biosciences has led to the clinical advancement of a small molecule drug targeting aging, showcasing the potential of AI in pharmaceutical innovation [13][14]. Market Performance and Company Valuations - The report provides a valuation table for key companies in the AI healthcare sector, indicating projected net profits and market capitalizations for 2024 to 2027. For instance, Weining Health is projected to have a market cap of 31 billion with a net profit of 3.5 billion by 2026 [14].